Abbv stock forecast analysts’ Abbv stock forecast projects

Analysts’ Abbv stock forecast projects continued outperformance versus the S&P 500 healthcare sector index, leveraging patent-protected drugs and pipeline innovations. Technical charts reveal a strong support line near $162, keeping downside risk limited in near term. We'll look at how AbbVie's continued investment in US biologics manufacturing capacity could reshape its longer-term growth outlook. Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.02 to $12.28 per share. ABBV boasts an average earnings surprise of 2.6%. Market sentiment on Abbv stock forecast is optimistic, supported by strong quarterly free cash flow exceeding $5 billion. YTD performance has outpaced sector peers, indicating healthy institutional inflows and reaffirming the bullish narrative.